There were 22 men with progressive mCRPC enrolled, the median age at enrollment was 66 years (range 52-80), the median PSA at original diagnosis was 82 ng/mL (range 5-3,648), 55% had a Gleason score 9 ...

Notably, treatment usage trends from a Bladder Cancer Advocacy Network (BCAN) survey presented at GU ASCO 2025 revealed that only 1–5% of patients reported having seen a radiation oncologist and only ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Wulff-Burchfield discussed strategies ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Michael Hofman presented an in-depth ...

ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Shilpa Gupta discussing FGFR3 alteration status and outcomes with immune checkpoint inhibitors in patients with ...

The investigators undertook a retrospective analysis of patients with advanced urothelial carcinoma who were longitudinally tested for ctDNA (MTM/mL) with a tumor-informed assay while on treatment ...

ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Scott T. Tagawa discussing ProstACT Global, a phase 3 study of 177 Lu-rosptamab + standard of care ...

Dr. Gay concluded his presentation discussing phase l results of a trial assessing radium-223, peposertib, and avelumab in advanced mCRPC with the following take home points: The combination of radium ...

ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Geoffrey Johnson discussing SECuRE, a dose escalation/expansion study to assess the anti-tumor ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. April Rose discussing a ctDNA–directed phase II study of carboplatin in patients with ...

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

Zachary Klaassen speaks with Pedro Barata about chemohormonal therapy and treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Barata traces the evolution from 2015 when ...